Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Latitude Investment Management's 2025 annual letter highlights a strong year of performance, with the portfolio gaining 21% in sterling terms. Utilizing Ralph Wanger's...
— Freddie Lait
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Royalty Pharma
Royalty Pharma plc is the industry's largest buyer of biopharmaceutical royalties, partnering with innovators to co-fund late-stage clinical trials and acquiring existing royalties on approved therapi
Royalty Pharma offers highly defensive, diversified royalty income streams at a very low valuation of 5.9x forward earnings. Led by a...